IL1-blocking therapy in colchicine-resistant familial Mediterranean fever
Yıl: 2018 Cilt: 5 Sayı: 4 Sayfa Aralığı: 230 - 234 Metin Dili: İngilizce DOI: 10.5152/eurjrheum.2018.18036 İndeks Tarihi: 15-10-2019
IL1-blocking therapy in colchicine-resistant familial Mediterranean fever
Öz: Objective: Approximately 10%-20% of patients with familial Mediterranean fever (FMF) show aninadequate response to colchicine. In our cohort study, patients with FMF with or without amyloi-dosis and with an inadequate response to colchicine were treated with anakinra or canakinumab.Methods: Clinical and laboratory parameters, Mediterranean fever (MEFV) mutations, and pa-tient-reported outcomes were analyzed in 31 patients treated with anakinra or canakinumab.Results: In a cohort of 250 adult patients with FMF, 31 patients were treated with anakinra (n=29) orcanakinumab (n=2). The median Pras FMF severity score was 8 (range, 5-14) and correlated with thepresence of high-penetrance MEFV mutations (p.Met-694-Val or p.Met-680-Ile). The FMF severityscore was 11 in patients with two high-penetrance MEFV mutations (68%), 9 in those with a singlehigh-penetrance MEFV mutation (19%), and 7.5 in those without high-penetrance MEFV mutations(13%, p=0.2). FMF-related amyloid A amyloidosis was diagnosed in 12 (39%) patients. Anakinra wasused daily in 20 patients, thrice a week in 7, and upon demand during attacks in 2. Two patientswere treated with canakinumab. IL-1-blocking treatment showed a rapid (2±3 days) and persistentsuppression of FMF symptoms and inflammatory parameters. The frequency of FMF attacks wassignificantly reduced (p<0.003). Both patient- and physician-reported FMF activity significantly im-proved (p<0.0001).Conclusion: IL-1-blocking therapy was well tolerated over a median period of 2 years and reducedthe frequency of FMF attacks in patients with colchicine-resistant FMF.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Ben-Chetrit E, Touitou I. Familial Mediterranean fever in the world. Arthritis Rheum 2009; 61: 1447-53. [CrossRef]
- Sohar E, Gafni J, Pras M, Heller H. Familial Med- iterranean fever. A survey of 470 cases and re- view of the literature. Am J Med 1967; 43: 227- 53. [CrossRef]
- Tunca M, Akar S, Onen F, Ozdogan H, Kasap- copur O, Yalcinkaya F, et al. Turkish FMF Study Group. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine 2005; 84: 1-11. [CrossRef]
- French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997; 17: 25-31. [CrossRef]
- The International FMF consortium: Ancient mis- sense mutations in a new member of the RoRet gene family are likely to cause familial Mediter- ranean fever. Cell 1997; 90: 797-807. [CrossRef]
- Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med 1972; 287: 1302. [CrossRef]
- Zemer D, Revach M, Pras M, Modan B, Schor S, Sohar E, et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fe- ver. N Engl J Med 1974; 291: 932-4. [CrossRef]
- Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW. Colchicine therapy for familial med- iterranean fever. A double-blind trial. N Engl J Med 1974; 291: 934-7 [CrossRef]
- Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 2016; 75: 644-51. [CrossRef]
- Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet 1998; 351: 659-64. [CrossRef]
- Ozen S, Kone-Paut I, Gül A. Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. Se- min Arthritis Rheum 2017; 47: 115-20. [CrossRef]
- Akar S, Cetin P, Kalyoncu U, Karadag O, Sari I, Cınar M, et al. Nationwide Experience with Off-Label Use of Interleukin-1 Targeting Treat- ment in Familial Mediterranean Fever Patients. Arthritis Care Res 2017; 70: 1090-4. [CrossRef]
- Mitroulis I, Papadopoulos VP, Konstantinidis T, Ritis K. Anakinra suppresses familial Mediterra- nean fever crises in a colchicine-resistant pa- tient. Neth J Med 2008; 66: 489-91.
- Moser C, Pohl G, Haslinger I, Knapp S, Row- czenio D, Russel T, et al. Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Nephrol Dial Transplant 2009; 24: 676-8. [CrossRef]
- Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchi- cine. J Rheumatol 2011; 38: 516-8. [CrossRef]
- Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Kone-Paut I. Interleukin-1 targeting drugs in familial Mediterranean fever: a case se- ries and a review of the literature. Semin Arthri- tis Rheum 2011; 41: 265-71. [CrossRef]
- Stankovic Stojanovic K, Delmas Y, Torres PU, Pel- tier J, Pelle G, Jeru I. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant 2012; 27: 1898-901. [CrossRef]
- Alpay N, Sumnu A, Calıskan Y, Yazıcı H, Turkmen A, Gul A. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int 2012; 32: 3277-9. [CrossRef]
- Eroglu FK, Besbas N, Topaloglu R, Ozen S. Treat- ment of colchicine-resistant Familial Mediterra- nean fever in children and adolescents. Rheu- matol Int 2015; 35: 1733-7. [CrossRef]
- Basaran O, Uncu N, Celikel BA, Taktak A, Gur G, Ca- kar N. Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric pa- tients. Mod Rheumatol 2015; 25: 621-4. [CrossRef]
- Cetin P, Sari I, Sozeri B, Cam O, Birlik M, Akkoc N. Efficacy of interleukin-1 targeting treatments in patients with familial Mediterranean fever. Inflammation 2015; 38: 27-31. [CrossRef]
- Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997; 40: 1879-85. [CrossRef]
- Pras E, Livneh A, Balow JE Jr, Pras E, Kastner DL, Pras M, et al. Clinical differences between North African and Iraqi Jews with familial Mediterranean fever. Am J Med Genet 1998; 75: 216-9.
- Ozen S, Demirkaya E, Duzova A, Erdogan O, Erken E, Gul A, et al. FMF50: a score for assessing outcome in familial Mediterranean fever. Ann Rheum Dis 2014; 73: 897-901. [CrossRef]
- Ben-Zvi I, Kukuy O, Giat E, Pras E, Feld O, Kivi- ty S, et al. Anakinra for Colchicine-Resistant Familial Mediterranean Fever: A Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 2017; 69: 854-62. [CrossRef]
- Kucuksahin O, Yildizgoren MT, Ilgen U, Ates A, Kinikli G, Turgay M, et al. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever. Mod Rheumatol 2017; 27: 350-5. [CrossRef]
- Kaiser C, Knight A, Nordström D, Pettersson T, Fransson J, Florin-Robertsson E, et al. Injec- tion-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int 2012; 32: 295-9. [CrossRef]
- De Benedetti F, Gattorno M, Anton J, Ben-Chet- rit E, Frenkel J, Hoffman HM, et al. Canakinumab for the Treatment of Autoinflammatory Recur- rent Fever Syndromes. N Engl J Med 2018; 378: 1908-19. [CrossRef]
- Granowitz EV, Porat R, Mier JW, Pribble JP, Stiles DM, Bloedow DC, et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992; 4: 353-60. [CrossRef]
- Omenetti A, Carta S, Delfino L, Martini A, Gattor- no M, Rubartelli A. Increased NLRP3-dependent interleukin 1β secretion in patients with familial Mediterranean fever: correlation with MEFV gen- otype. Ann Rheum Dis 2014; 73: 462-9. [CrossRef]
- Kallinich T, Orak B, Wittkowski H. Role of genetics in familial Mediterranean fever. Review in Ger- man. Z Rheumatol 2017; 76: 303-12. [CrossRef]
- Bonfrate L, Scaccianoce G, Palasciano G, Ben-Chetrit E, Portincasa P. A novel cluster of patients with Familial Mediterranean Fever (FMF) in southern Italy. Eur J Clin Invest 2017; 47: 622-9. [CrossRef]
| APA | KÖHLER B, LORENZ H, BLANK N (2018). IL1-blocking therapy in colchicine-resistant familial Mediterranean fever. , 230 - 234. 10.5152/eurjrheum.2018.18036 |
| Chicago | KÖHLER Birgit Maria,LORENZ Hanns Martin,BLANK Norbert IL1-blocking therapy in colchicine-resistant familial Mediterranean fever. (2018): 230 - 234. 10.5152/eurjrheum.2018.18036 |
| MLA | KÖHLER Birgit Maria,LORENZ Hanns Martin,BLANK Norbert IL1-blocking therapy in colchicine-resistant familial Mediterranean fever. , 2018, ss.230 - 234. 10.5152/eurjrheum.2018.18036 |
| AMA | KÖHLER B,LORENZ H,BLANK N IL1-blocking therapy in colchicine-resistant familial Mediterranean fever. . 2018; 230 - 234. 10.5152/eurjrheum.2018.18036 |
| Vancouver | KÖHLER B,LORENZ H,BLANK N IL1-blocking therapy in colchicine-resistant familial Mediterranean fever. . 2018; 230 - 234. 10.5152/eurjrheum.2018.18036 |
| IEEE | KÖHLER B,LORENZ H,BLANK N "IL1-blocking therapy in colchicine-resistant familial Mediterranean fever." , ss.230 - 234, 2018. 10.5152/eurjrheum.2018.18036 |
| ISNAD | KÖHLER, Birgit Maria vd. "IL1-blocking therapy in colchicine-resistant familial Mediterranean fever". (2018), 230-234. https://doi.org/10.5152/eurjrheum.2018.18036 |
| APA | KÖHLER B, LORENZ H, BLANK N (2018). IL1-blocking therapy in colchicine-resistant familial Mediterranean fever. European Journal of Rheumatology, 5(4), 230 - 234. 10.5152/eurjrheum.2018.18036 |
| Chicago | KÖHLER Birgit Maria,LORENZ Hanns Martin,BLANK Norbert IL1-blocking therapy in colchicine-resistant familial Mediterranean fever. European Journal of Rheumatology 5, no.4 (2018): 230 - 234. 10.5152/eurjrheum.2018.18036 |
| MLA | KÖHLER Birgit Maria,LORENZ Hanns Martin,BLANK Norbert IL1-blocking therapy in colchicine-resistant familial Mediterranean fever. European Journal of Rheumatology, vol.5, no.4, 2018, ss.230 - 234. 10.5152/eurjrheum.2018.18036 |
| AMA | KÖHLER B,LORENZ H,BLANK N IL1-blocking therapy in colchicine-resistant familial Mediterranean fever. European Journal of Rheumatology. 2018; 5(4): 230 - 234. 10.5152/eurjrheum.2018.18036 |
| Vancouver | KÖHLER B,LORENZ H,BLANK N IL1-blocking therapy in colchicine-resistant familial Mediterranean fever. European Journal of Rheumatology. 2018; 5(4): 230 - 234. 10.5152/eurjrheum.2018.18036 |
| IEEE | KÖHLER B,LORENZ H,BLANK N "IL1-blocking therapy in colchicine-resistant familial Mediterranean fever." European Journal of Rheumatology, 5, ss.230 - 234, 2018. 10.5152/eurjrheum.2018.18036 |
| ISNAD | KÖHLER, Birgit Maria vd. "IL1-blocking therapy in colchicine-resistant familial Mediterranean fever". European Journal of Rheumatology 5/4 (2018), 230-234. https://doi.org/10.5152/eurjrheum.2018.18036 |
